Human B2M/beta 2-Microglobulin Protein, Ultra Low Endotoxin

Cat. No. B2M-HM201-UL

Description

Source	Recombinant Human B2M/beta 2-Microglobulin Protein is expressed from HEK293 with hFc (IgG1) tag at the C-Terminus.
	It contains Ile21-Met119.
Accession	P61769-1
Molecular Weight	The protein has a predicted MW of 38.4 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 0.01 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

To assess whether beta-2 microglobulin (B2M) has effects on articular chondrocytes that would implicate B2M involvement in osteoarthritis (OA) pathogenesis.The average B2M level in OA synovial fluid is significantly higher than that found in normal synovial fluid. B2M is highly expressed in OA cartilage and synovial fluid compared to normal, and suggest that B2M may have effects on chondrocyte function that could contribute to OA pathogenesis.

Assay Data

Bis-Tris PAGE



Human B2M on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Human B2M/beta 2-Microglobulin Protein, Ultra Low Endotoxin

Cat. No. B2M-HM201-UL

Assay Data



The purity of Human B2M is greater than 95% as determined by SEC-HPLC.